-
PurposeReporter construct for NF‐κB activation. Contains two copies of immunoglobulin kappa light chain motif (5′‐GGGGACTTTCC‐3′) upstream of the a minimal promoter driving luciferase expression
-
Depositing Lab
-
Publication
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 14886 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonena
- Backbone size w/o insert (bp) 5800
-
Vector typeMammalian Expression, Luciferase
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameIgK-IFN
-
Alt nameIFNB1
-
Alt nameIgK2‐IFN‐LUC reporter
-
SpeciesH. sapiens (human)
-
Insert Size (bp)80
-
Entrez GeneIFNB1 (a.k.a. IFB, IFF, IFN-beta, IFNB)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site SacII (not destroyed)
- 3′ cloning site HindIII (not destroyed)
- 5′ sequencing primer na
- 3′ sequencing primer LucNrev (Common Sequencing Primers)
Resource Information
-
Articles Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Contains two copies of the immunoglobulin kappa light chain kappa-B site (5'-GGGGACTTTCC-3') upstream of the interferon-beta minimal promoter (–55 to +19) (Fujita et al., 1987) driving luciferase expression.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
IgK-IFN-luc was a gift from David Baltimore (Addgene plasmid # 14886 ; http://n2t.net/addgene:14886 ; RRID:Addgene_14886) -
For your References section:
CARD11 mediates factor-specific activation of NF-kappaB by the T cell receptor complex. Pomerantz JL, Denny EM, Baltimore D. EMBO J. 2002 Oct 1. 21(19):5184-94. 10.1093/emboj/cdf505 PubMed 12356734